Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial

Publication | Closed Access

DOI

Citations

References

2024

Year

Paul Kim, Ana M. Sánchez, Taylor J.R. Penke, Hannah H. Tuson, J. Kime, Robert W. McKee, William L. Slone, Nicholas R. Conley, Lana J. McMillan, Cameron J. Prybol,

The Lancet Infectious Diseases

Antimicrobial SusceptibilityAntibioticsCrispr-cas3-enhanced Bacteriophage CocktailBacteriophageAntimicrobial ResistanceEscherichia ColiProkaryotic VirusGenome EditingMicrobiologyInfection ControlTwo-part Phase 2Phage BiologyMedicineClinical MicrobiologyCrispr